Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
12
SY Quote, Financials, Valuation and Earnings
Last price:
$2.53
Seasonality move
:
-25.91%
Day range:
$2.45 - $2.66
52-week range:
$0.67 - $6.28
Dividend yield:
0%
P/E ratio:
17.47x
P/S ratio:
1.27x
P/B ratio:
1.25x
Volume:
1.7M
Avg. volume:
869.6K
1-year change:
203.58%
Market cap:
$248.1M
Revenue:
$203.8M
EPS (TTM):
-$1.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SY
So-Young International, Inc.
|
$53.8M | -$0.05 | 21.94% | -88.37% | $5.62 |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SY
So-Young International, Inc.
|
$2.49 | $5.62 | $248.1M | 17.47x | $0.03 | 0% | 1.27x |
|
ADAG
Adagene, Inc.
|
$1.79 | $9.22 | $84.3M | -- | $0.00 | 0% | 805.60x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.77 | $4.00 | $15.9M | -- | $0.00 | 0% | 0.45x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.24 | -- | $4M | -- | $0.00 | 0% | 1.00x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$17.82 | $49.17 | $2B | -- | $0.00 | 0% | 4.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SY
So-Young International, Inc.
|
13.72% | 9.138 | 9.27% | 1.51x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SY
So-Young International, Inc.
|
$25.5M | -$10.2M | -32.55% | -36.65% | -18.81% | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
So-Young International, Inc. vs. Competitors
-
Which has Higher Returns SY or ADAG?
Adagene, Inc. has a net margin of -16.77% compared to So-Young International, Inc.'s net margin of --. So-Young International, Inc.'s return on equity of -36.65% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital SYSo-Young International, Inc.47.29% -$0.09 $289M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About SY or ADAG?
So-Young International, Inc. has a consensus price target of $5.62, signalling upside risk potential of 125.81%. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 415.32%. Given that Adagene, Inc. has higher upside potential than So-Young International, Inc., analysts believe Adagene, Inc. is more attractive than So-Young International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYSo-Young International, Inc.2 0 0 ADAGAdagene, Inc.6 2 0 -
Is SY or ADAG More Risky?
So-Young International, Inc. has a beta of 1.970, which suggesting that the stock is 96.98% more volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SY or ADAG?
So-Young International, Inc. has a quarterly dividend of $0.03 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. So-Young International, Inc. pays 7.42% of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend. So-Young International, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SY or ADAG?
So-Young International, Inc. quarterly revenues are $54M, which are larger than Adagene, Inc. quarterly revenues of --. So-Young International, Inc.'s net income of -$9.1M is higher than Adagene, Inc.'s net income of --. Notably, So-Young International, Inc.'s price-to-earnings ratio is 17.47x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for So-Young International, Inc. is 1.27x versus 805.60x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYSo-Young International, Inc.1.27x 17.47x $54M -$9.1M ADAGAdagene, Inc.805.60x -- -- --
-
Which has Higher Returns SY or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -16.77% compared to So-Young International, Inc.'s net margin of -353.92%. So-Young International, Inc.'s return on equity of -36.65% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital SYSo-Young International, Inc.47.29% -$0.09 $289M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About SY or CASI?
So-Young International, Inc. has a consensus price target of $5.62, signalling upside risk potential of 125.81%. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 417.6%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than So-Young International, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than So-Young International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYSo-Young International, Inc.2 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is SY or CASI More Risky?
So-Young International, Inc. has a beta of 1.970, which suggesting that the stock is 96.98% more volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock SY or CASI?
So-Young International, Inc. has a quarterly dividend of $0.03 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. So-Young International, Inc. pays 7.42% of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. So-Young International, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SY or CASI?
So-Young International, Inc. quarterly revenues are $54M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. So-Young International, Inc.'s net income of -$9.1M is higher than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, So-Young International, Inc.'s price-to-earnings ratio is 17.47x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for So-Young International, Inc. is 1.27x versus 0.45x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYSo-Young International, Inc.1.27x 17.47x $54M -$9.1M CASICASI Pharmaceuticals, Inc.0.45x -- $3.1M -$10.9M
-
Which has Higher Returns SY or CPHI?
China Pharma Holdings, Inc. has a net margin of -16.77% compared to So-Young International, Inc.'s net margin of -86.16%. So-Young International, Inc.'s return on equity of -36.65% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital SYSo-Young International, Inc.47.29% -$0.09 $289M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About SY or CPHI?
So-Young International, Inc. has a consensus price target of $5.62, signalling upside risk potential of 125.81%. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that So-Young International, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe So-Young International, Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYSo-Young International, Inc.2 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is SY or CPHI More Risky?
So-Young International, Inc. has a beta of 1.970, which suggesting that the stock is 96.98% more volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock SY or CPHI?
So-Young International, Inc. has a quarterly dividend of $0.03 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. So-Young International, Inc. pays 7.42% of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend. So-Young International, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SY or CPHI?
So-Young International, Inc. quarterly revenues are $54M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $756.2K. So-Young International, Inc.'s net income of -$9.1M is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, So-Young International, Inc.'s price-to-earnings ratio is 17.47x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for So-Young International, Inc. is 1.27x versus 1.00x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYSo-Young International, Inc.1.27x 17.47x $54M -$9.1M CPHIChina Pharma Holdings, Inc.1.00x -- $756.2K -$651.5K
-
Which has Higher Returns SY or SVA?
Sinovac Biotech Ltd. has a net margin of -16.77% compared to So-Young International, Inc.'s net margin of --. So-Young International, Inc.'s return on equity of -36.65% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital SYSo-Young International, Inc.47.29% -$0.09 $289M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About SY or SVA?
So-Young International, Inc. has a consensus price target of $5.62, signalling upside risk potential of 125.81%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that So-Young International, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe So-Young International, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SYSo-Young International, Inc.2 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is SY or SVA More Risky?
So-Young International, Inc. has a beta of 1.970, which suggesting that the stock is 96.98% more volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock SY or SVA?
So-Young International, Inc. has a quarterly dividend of $0.03 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. So-Young International, Inc. pays 7.42% of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend. So-Young International, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SY or SVA?
So-Young International, Inc. quarterly revenues are $54M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. So-Young International, Inc.'s net income of -$9.1M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, So-Young International, Inc.'s price-to-earnings ratio is 17.47x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for So-Young International, Inc. is 1.27x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYSo-Young International, Inc.1.27x 17.47x $54M -$9.1M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns SY or ZLAB?
Zai Lab Ltd. has a net margin of -16.77% compared to So-Young International, Inc.'s net margin of -30.98%. So-Young International, Inc.'s return on equity of -36.65% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital SYSo-Young International, Inc.47.29% -$0.09 $289M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About SY or ZLAB?
So-Young International, Inc. has a consensus price target of $5.62, signalling upside risk potential of 125.81%. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 175.93%. Given that Zai Lab Ltd. has higher upside potential than So-Young International, Inc., analysts believe Zai Lab Ltd. is more attractive than So-Young International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYSo-Young International, Inc.2 0 0 ZLABZai Lab Ltd.8 1 0 -
Is SY or ZLAB More Risky?
So-Young International, Inc. has a beta of 1.970, which suggesting that the stock is 96.98% more volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock SY or ZLAB?
So-Young International, Inc. has a quarterly dividend of $0.03 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. So-Young International, Inc. pays 7.42% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend. So-Young International, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SY or ZLAB?
So-Young International, Inc. quarterly revenues are $54M, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. So-Young International, Inc.'s net income of -$9.1M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, So-Young International, Inc.'s price-to-earnings ratio is 17.47x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for So-Young International, Inc. is 1.27x versus 4.33x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYSo-Young International, Inc.1.27x 17.47x $54M -$9.1M ZLABZai Lab Ltd.4.33x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
